Novel and Difficult Targets in Antibody Drug Discovery

Novel and Difficult Targets in Antibody Drug DiscoveryTarget specificity, protein degradation and bispecific antibodies: leading methods and strategies in handling novel and difficult targets in antibody-based drug discoveryIn this ebook, we explore leading strategies in handling novel and difficult targets in therapeutic antibody discovery.Contents

Introduction

Rated the most important area of antibody therapeutic development by industry professionals earlier this year, novel targets for therapeutic antibodies incur their own challenges in the discovery process.

In this ebook, we explore leading strategies in handling novel and difficult targets in therapeutic antibody discovery, including transforming targets or using innovative platforms to overcome the obstacles.

We invite you to join us as we look at insights from Genovac, Genscript, Retrogenix and more.

Jump to any article using the contents on the following page, or at any time using the Contents menu in the top left. There you can also download this eBook as a PDF.

1. Antibody discovery is the biggest challenge in antibody therapeutics

Therapeutic development and technology challenges: Key data and insights from the REPORT: Antibody Engineering & Therapeutics State of the Industry 2021.

2. Transforming therapeutic targets

Leading researchers discuss the challenges and methods of transforming therapeutic targets for antibody-based treatments.

3. Therapeutic antibody discovery using integrated multi-modality platform

A whitepaper by Genscript on exploring novel MOA and validating bi-specific antibodies against PD-1 and TIGIT.

4. Uncovering critical receptors and assessing target specificity of biotherapeutics

A presentation on assessing the target specificity of biotherapeutics by Diogo Rodrigues Ferreirinha at Retrogenix Limited.

5. Novel non-cancer targets for therapeutic antibodies

Animal models, human-derived antibodies and macular generation: Industry leaders developing non-cancer targets for therapeutic antibodies reveal their work so far.

6. Leading strategies for antibody discovery against difficult targets

A presentation on innovative antibody discovery by Amelie Kutschera & Iwona Budnicki at Genovac.

7. Development of antibody-based degraders for difficult-to-target proteins

Protein degradation, isdAbs and screening: We explore a key presentation by Nicolas Bery at Cancer Research Centre of Toulouse CRCT.